327 related articles for article (PubMed ID: 32675396)
1. Expression of cancer stem cell markers in breast phyllodes tumor.
Kim SI; Koo JS
Cancer Biomark; 2020; 29(2):235-243. PubMed ID: 32675396
[TBL] [Abstract][Full Text] [Related]
2. Stromal cells in phyllodes tumors of the breast are enriched for EZH2 and stem cell marker expression.
Zhang Y; Liss AL; Chung E; Pierce LJ; Kleer CG
Breast Cancer Res Treat; 2016 Jul; 158(1):21-28. PubMed ID: 27290698
[TBL] [Abstract][Full Text] [Related]
3. Analysis of phyllodes tumor recurrence according to the histologic grade.
Kim S; Kim JY; Kim DH; Jung WH; Koo JS
Breast Cancer Res Treat; 2013 Oct; 141(3):353-63. PubMed ID: 24062207
[TBL] [Abstract][Full Text] [Related]
4. Co-expression of stem cell markers ALDH1 and CD44 in non-malignant and neoplastic lesions of the breast.
DA Cruz Paula A; Marques O; Rosa AM; DE Fátima Faria M; Rêma A; Lopes C
Anticancer Res; 2014 Mar; 34(3):1427-34. PubMed ID: 24596390
[TBL] [Abstract][Full Text] [Related]
5. In phyllodes tumour of the breast expression of c-kit but not of ALDH1A1 is associated with adverse clinico-pathological features.
Chougule A; Bal A; Das A; Kohli PS; Singh G
Virchows Arch; 2016 Dec; 469(6):651-658. PubMed ID: 27696244
[TBL] [Abstract][Full Text] [Related]
6. Expression of Yes-associated protein (YAP) in breast phyllodes tumor.
Kim SK; Jung WH; Koo JS
Int J Clin Exp Pathol; 2014; 7(9):5997-6005. PubMed ID: 25337244
[TBL] [Abstract][Full Text] [Related]
7. Phyllodes tumors of the breast: clinicopathological analysis of 106 cases from a single institution.
Efared B; Ebang GA; Tahiri L; Sidibé IS; Erregad F; Hammas N; Melhouf MA; Banani A; Chbani L; Fatemi HE
Breast Dis; 2018; 37(3):139-145. PubMed ID: 29332027
[TBL] [Abstract][Full Text] [Related]
8. The Prognostic Value of Cancer Stem Cell Markers (Notch1, ALDH1, and CD44) in Primary Colorectal Carcinoma.
Mohamed SY; Kaf RM; Ahmed MM; Elwan A; Ashour HR; Ibrahim A
J Gastrointest Cancer; 2019 Dec; 50(4):824-837. PubMed ID: 30136202
[TBL] [Abstract][Full Text] [Related]
9. Expression of EMP1, EMP2, and EMP3 in breast phyllodes tumors.
Cha YJ; Koo JS
PLoS One; 2020; 15(8):e0238466. PubMed ID: 32857809
[TBL] [Abstract][Full Text] [Related]
10. Phyllodes tumor of the breast: a retrospective study of the impact of histopathological factors in local recurrence and distant metastasis.
Sawalhi S; Al-Shatti M
Ann Saudi Med; 2013; 33(2):162-8. PubMed ID: 23563006
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors in phyllodes tumours of the breast: retrospective study on 166 consecutive cases.
Di Liso E; Bottosso M; Lo Mele M; Tsvetkova V; Dieci MV; Miglietta F; Falci C; Faggioni G; Tasca G; Giorgi CA; Giarratano T; Mioranza E; Michieletto S; Saibene T; Dei Tos AP; Conte P; Guarneri V
ESMO Open; 2020 Oct; 5(5):e000843. PubMed ID: 33020219
[TBL] [Abstract][Full Text] [Related]
12. ALDH1 is a better clinical indicator for relapse of invasive ductal breast cancer than the CD44+/CD24- phenotype.
Zhong Y; Shen S; Zhou Y; Mao F; Guan J; Lin Y; Xu Y; Sun Q
Med Oncol; 2014 Mar; 31(3):864. PubMed ID: 24519209
[TBL] [Abstract][Full Text] [Related]
13. Phyllodes tumor of the breast: stromal overgrowth and histological classification are useful prognosis-predictive factors for local recurrence in patients with a positive surgical margin.
Taira N; Takabatake D; Aogi K; Ohsumi S; Takashima S; Nishimura R; Teramoto N
Jpn J Clin Oncol; 2007 Oct; 37(10):730-6. PubMed ID: 17932112
[TBL] [Abstract][Full Text] [Related]
14. The role of ALDH1A1 in contributing to breast tumour aggressiveness: A study conducted in an African population.
Gyan E; Green A; Ahenkorah-Fondjo L; Jackson A; Toss MS; Akakpo PK; Derkyi-Kwarteng L; Rahman GA; Owiredu W
Ann Diagn Pathol; 2021 Apr; 51():151696. PubMed ID: 33460998
[TBL] [Abstract][Full Text] [Related]
15. Molecules involved in epithelial-mesenchymal transition and epithelial-stromal interaction in phyllodes tumors: implications for histologic grade and prognosis.
Kwon JE; Jung WH; Koo JS
Tumour Biol; 2012 Jun; 33(3):787-98. PubMed ID: 22203494
[TBL] [Abstract][Full Text] [Related]
16. Epithelial-mesenchymal transition and cancer stem cell interactions in breast phyllodes tumours: immunohistochemical evaluation of EZH2, EZR, HMGA2, CD24 and CD44 in correlation with outcome analysis.
Ahmed SS; Lim JCT; Thike AA; Iqbal J; Tan PH
J Clin Pathol; 2022 May; 75(5):316-323. PubMed ID: 33627375
[TBL] [Abstract][Full Text] [Related]
17. An approach to malignant mammary phyllodes tumors detection.
Ilić I; Randelović P; Ilić R; Katić V; Milentijević M; Velicković L; Krstić M
Vojnosanit Pregl; 2009 Apr; 66(4):277-82. PubMed ID: 19441158
[TBL] [Abstract][Full Text] [Related]
18. E-cadherin expression in the epithelial components of mammary phyllodes tumors.
Tsang JY; Mendoza P; Putti TC; Karim RZ; Scolyer RA; Lee CS; Pang AL; Tse GM
Hum Pathol; 2012 Dec; 43(12):2117-23. PubMed ID: 22820000
[TBL] [Abstract][Full Text] [Related]
19. Stromal matrix metalloproteinase-14 expression correlates with the grade and biological behavior of mammary phyllodes tumors.
Kim GE; Kim JH; Lee KH; Choi YD; Lee JS; Lee JH; Nam JH; Choi C; Park MH; Yoon JH
Appl Immunohistochem Mol Morphol; 2012 May; 20(3):298-303. PubMed ID: 22505012
[TBL] [Abstract][Full Text] [Related]
20. Importance of P53, Ki-67 expression in the differential diagnosis of benign/malignant phyllodes tumors of the breast.
Kucuk U; Bayol U; Pala EE; Cumurcu S
Indian J Pathol Microbiol; 2013; 56(2):129-34. PubMed ID: 24056649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
